Recombinant lentivector as a genetic immunization vehicle for antitumor immunity.
about
Nonintegrating lentiviral vectors can effectively deliver ovalbumin antigen for induction of antitumor immunity.Immunization delivered by lentiviral vectors for cancer and infectious diseases.Production of lentiviral vectors with enhanced efficiency to target dendritic cells by attenuating mannosidase activity of mammalian cells.Lentivector immunization stimulates potent CD8 T cell responses against melanoma self-antigen tyrosinase-related protein 1 and generates antitumor immunity in mice.Lentivector expressing HBsAg and immunoglobulin Fc fusion antigen induces potent immune responses and results in seroconversion in HBsAg transgenic mice.Construction of stable producer cells to make high-titer lentiviral vectors for dendritic cell-based vaccination.Immunoglobulin Fc fragment tagging allows strong activation of endogenous CD4 T cells to reshape the tumor milieu and enhance the antitumor effect of lentivector immunization.A TLR4 agonist synergizes with dendritic cell-directed lentiviral vectors for inducing antigen-specific immune responsesDirecting dendritic cell immunotherapy towards successful cancer treatment.Targeting lentiviral vectors for cancer immunotherapy.Lentiviral vectors for cancer immunotherapy and clinical applicationsSuccessful therapeutic vaccination with integrase defective lentiviral vector expressing nononcogenic human papillomavirus E7 protein.Lentiviral vectors transduce proliferating dendritic cell precursors leading to persistent antigen presentation and immunization.Dendritic cell immunotherapy.Dendritic cell-directed lentivector vaccine induces antigen-specific immune responses against murine melanoma.
P2860
Q33564383-FA9850B4-AB6D-487B-AC3C-58BD94FEBCB9Q34539879-16E716B6-0D65-46B8-B9F5-E1D7A0455D03Q34576498-9EB2843D-5BB4-4AB7-83D3-4E74C3B44BF5Q34801323-9B973536-6720-48AE-AF64-AED518F882B4Q34958663-1A8AE801-4D20-44B3-A1F9-B614144F435BQ35899079-94203923-5284-4068-A0B0-EEE55A6839EAQ35982675-D75C9D49-313A-4438-912A-C0655382B9C0Q35990046-F7DF476C-5B64-4595-8198-BFF15C5F7D8EQ37754014-9679058C-B91A-4B7F-B419-A7ADBEE0951EQ38043924-839DE606-A2C7-4AB4-8213-B6C4774C7640Q38147100-50FD1A5C-2435-43B1-8EB4-67F34298A453Q39330979-2D35D958-89C6-4D0A-A34C-B3F18BF7A206Q39511106-B7494119-C362-4033-A832-F03CC04ACCE5Q44483910-7C41B4D9-4176-43D1-9B3B-55AC6D152565Q46932503-736AADD3-809C-4A80-8AB1-AA0BF4FC502B
P2860
Recombinant lentivector as a genetic immunization vehicle for antitumor immunity.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Recombinant lentivector as a genetic immunization vehicle for antitumor immunity.
@en
Recombinant lentivector as a genetic immunization vehicle for antitumor immunity.
@nl
type
label
Recombinant lentivector as a genetic immunization vehicle for antitumor immunity.
@en
Recombinant lentivector as a genetic immunization vehicle for antitumor immunity.
@nl
prefLabel
Recombinant lentivector as a genetic immunization vehicle for antitumor immunity.
@en
Recombinant lentivector as a genetic immunization vehicle for antitumor immunity.
@nl
P2093
P2860
P356
P1476
Recombinant lentivector as a genetic immunization vehicle for antitumor immunity.
@en
P2093
David Munn
Louis D Falo
P2860
P304
P356
10.1586/14760584.6.6.913
P577
2007-12-01T00:00:00Z